Gliptins with increasing supply relevance
The drug therapy for type 2 diabetes mellitus is being put to the test again with the stock market call on April 1, 2013. As early as 2011, every second euro of oral antidiabetic drugs (OADs) was spent on DPP-IV inhibitors (cf. Bensing/Kleinfeld 2012), and this share has now increased to almost 63 percent. The significant increases in expenditure (according to list prices) for OAD tend to be offset by constant prescription quantities.
Read more
First publication date: 28.05.2013
Downloads
Additional Information
- Issue: Issue 03/2013 Publication Date: 28.05.2013 All issues as PDF Subscribe to print magazine Order single issue Open Access
